Eterna Therapeutics, a biopharmaceutical company based in Massachusetts, announced on Thursday the appointment of Dr. Elena Ratner, M.D., M.B.A., to its Board of Directors.
Dr. Ratner will play a crucial role in steering Eterna's strategic initiatives in ovarian cancer, leveraging her extensive expertise in the fields of obstetrics, gynecology, and reproductive sciences. Her leadership is set to propel the development of innovative therapies in women's health, bolstered by Eterna's recent collaboration with MD Anderson Cancer Center, which is concentrated on pioneering treatments for ovarian and breast cancers.
Dr. Ratner serves as a Professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at Yale University School of Medicine and is the Director of the Discovery to Cure Early Ovarian Cancer Detection program. Her exceptional contributions have been recognized with numerous awards, including the 2024 David and Cindy Leffell Clinical Excellence Award and the 2015 Yale Cancer Center Award for Clinical Excellence.
On Wednesday, Eterna's stock closed at $0.3233, reflecting a 3.03% decline. However, in after-hours trading, the stock increased, closing at $0.34, marking a 5.17% rise.
